Estrogen-receptor (ER) status is an important parameter in breast cancer management as ER-positive breast cancers have a better prognosis than ER-negative tumors. This difference comes essentially from the lower aggressiveness and invasiveness of ER-positive tumors. Here, we demonstrate, that interleukin-8 (IL-8) was clearly overexpressed in most ER-negative breast, ovary cell lines and breast tumor samples tested, whereas no significant IL-8 level could be detected in ER-positive breast or ovarian cell lines. We have also cloned human IL-8 from ERnegative MDA-MB-231 cells, and we show that IL-8 produced by breast cancer cells is identical to monocytederived IL-8. Interestingly, the invasion potential of ERnegative breast cancer cells is associated at least in part with expression of IL-8, but not with IL-8 receptor levels. Moreover, IL-8 increases the invasiveness of ER-positive breast cancer cells by two fold, thus confirming the invasion-promoting role of IL-8. On the other hand, exogenous expression of estrogen receptors in ERnegative cells led to a decrease of IL-8 levels. In summary, our data show that IL-8 expression is negatively linked to ER status of breast and ovarian cancer cells. We also support the idea that IL-8 expression is associated with a higher invasiveness potential of cancer cells in vitro, which suggests that IL-8 could be a novel marker of tumor aggressiveness.
Introduction
Breast cancer is one of the most frequent malignant neoplasm occurring in women in developed countries (Pisani, 1992) . Among the different prognostic factors, lack of estrogen receptor (ER) has been consistently associated with a poorer prognosis (Skoog et al., 1987) . Two estrogen receptors (ERa and ERb) have been identified (Green and Chambon, 1986; Mosselman et al., 1996) . Most human breast cancers, at least initially, express ERa, and the presence of ERa is generally considered as an indication of hormone-dependence, even though only 60% of ERa-positive tumors will respond to adjuvant therapy with tamoxifen (McGuire, 1975) . On the contrary, ERb expression is low in most breast and ovarian cancers compared to normal tissues (Pujol et al., 1998; Roger et al., 2001) . Owing to the low levels of ERb in breast and ovarian cancers, ER-positive status of samples of this study will refer to estrogenresponsive ERa-positive cells.
In the search of markers of cancer aggressiveness, interleukin-8 (IL-8) has been suspected to play an important role in breast cancer. Since metastasis represents the major remaining cause of mortality in human breast cancer, we sought to examine the possibility that increased metastatic potential (invasiveness) is associated with lack of ER and changes in IL-8 expression.
IL-8 is a 8.4 kDa protein belonging to the CXC subfamily of chemokines that is characterized by two essential cysteine residues, separated by a third intervening amino acid (Baggiolini et al., 1989; Matsushima and Oppenheim, 1989 ). There are two major forms of IL-8, the 72-amino acid monocyte-derived form, predominant in cultures of monocytes and macrophages, and the endothelial form, which has five extra N-terminal amino acids, predominant in cultures of tissue cells such as endothelial cells and fibroblasts (Terui et al., 1998) .
The two aims of the present study were to determine whether there are differences in IL-8 expression in human breast cancer cell lines with a particular attention to ER levels, and to investigate the effect of ectopic expression of IL-8 on proliferation and invasion of breast carcinoma cell lines.
Results
IL-8 is considered as a potential metastatic factor in breast cancers (De Larco et al., 2001) ; however, no study has investigated the potential involvement of IL-8 expression in the aggressiveness of ER negative breast cancers. Therefore, we have conducted a study on a collection of breast cancer cell lines to determine whether IL-8 was correlated to ER status, and whether differences in IL-8 expression could reflect the invasiveness potential of ER-negative and ER-positive breast cancer cells.
We first checked IL-8 expression in two different model cell lines: MDA-MB-231 (ER-negative) and MCF-7 (ER-positive) cells. By performing a Northern blot with an IL-8 probe, we observed a striking difference of IL-8 expression in MDA-MB-231 and MCF-7 cells. IL-8 was highly expressed in MDA-MB-231 cells and not detectable in MCF-7 cells (Figure 1a) . Moreover, E2 treatment did not affect IL-8 RNA levels in MCF-7 and MDA-MB-231 cells, but induced pS2 expression in MCF-7 cells, confirming the responsiveness of these cells (Figure 1a) . At the protein level, IL-8 was also restricted to MDA-MB-231 cells (Figure 1b) .
To determine the relevance of our observations, it was essential to ensure that IL-8 produced by MDA-MB-231 cells was functional. So, we cloned IL-8 present from MDA-MB-231 cells by performing RT-PCR with specific primers of human IL-8 cDNA. We isolated a fragment of IL-8 composed of the first 877 bp of the cDNA and containing the complete open reading frame of the protein (Figure 1c ). The sequencing revealed that IL-8 produced by MDA-MB-231 cells corresponds to the 99 aa precurser protein form of IL-8 with a classical 27 aa signal peptide, which is the most active IL-8 form (Figure 1d) .
We have then analyzed whether the overexpression of IL-8 in MDA-MB-231 cells was a general difference between ER-negative and ER-positive breast cancer cells. We selected three negative and three positive breast cancer cell lines to evaluate IL-8 expression by Northern blot (Figure 2) . Interestingly, none of the ERpositive cell lines expressed detectable levels of IL-8 RNA, whereas two ER-negative breast cancer lines (MDA-MB-231 and MDA-MB-436) were expressing high levels of IL-8 and SK-BR3 cells did not show significant levels of IL-8 (Figure 2 ). In addition, estradiol did not modify IL-8 expression in ER-negative or ER-positive cancer cells, whereas it strongly induced pS2 expression (a marker of estrogen responsiveness) in ER-positive cells.
As producing cells generally secrete IL-8, we then determined IL-8 secretion in a collection of breast and ovarian cancer cell lines, to assess whether this holds true for cancer cells in general. We analyzed IL-8 secretion by ER-negative and ER-positive breast cancer cells by ELISA (Figure 3a and b) . Interestingly, ERnegative breast cancer cells secreted variable amounts of IL-8 ranging from 0.1 to 336 ng IL-8/ml/48 h/million On the other hand, it was striking to observe that none of the ER-positive breast cancer cells tested secreted significant levels of IL-8. To evaluate whether this pattern of production was specific of breast cancer cells, we analyzed the IL-8 secretion of cervix carcinoma (Hela) and ovarian cancer cell lines (PEO14, BGl, PEO4) (Figure 3c ). There again, the same pattern was observed: no significant secretion of IL-8 by ER-positive cancer cells, and variable amounts of IL-8 secretion by ER-negative cancer cells. Very interestingly, the exogenous expression of ERa or ERb in Hela cells led to decreased expression of IL-8 of about 50% in these cells (Figure 3d ) confirming that ER presence was negatively linked to IL-8 expression. This led us to determine whether IL-8 expression could be correlated to ERb status. We first checked the estrogen-responsiveness of our cell lines by transient transfection assay with an estrogen-responsive reporter construct ( Figure 3e ). As expected, only ERa-positive cell lines (BT-474, CAMA-1, MCF-7, T47D, ZR-75-1, PEO4 and BGl) responded to estradiol. We then analyzed the ERb content of these cells by RT-PCR (Figure 3f ). We observed that ERb expression was variable and low among the different cell lines, with the exception of MDA-MB-468 cells. Considering the unresponsiveness of these cells, it is likely that the expression of ERb is either too low or leads to a mutated form of the protein.
But the most important conclusion is that we could not see any correlation between ERb and IL-8 levels.
To extend our in vitro observations on differential expression of IL-8 in ER-negative vs ER-positive cancer cells, we have analyzed IL-8 expression in 14 breast tumor samples by RT-PCR. The ERa and ERb-status was determined by RT-PCR (Figure 4a ) and by ELISA (Figure 4b ). First, we did not see by RT-PCR significant differences in terms of ERb expression among the 14 samples, whereas the ERa-status was in total agreement with the ELISA data. Furthermore, at a comparable amplification cycle number, ERb expression was weaker than the one of ERa (see the Materials and methods section). This confirms previous work from our laboratory, demonstrating that ERb expression was weak in breast tumors and that ER-positive samples are indeed ERa-positive (Brouillet et al., 2001) . We observed that most of the ER-negative tumors (5/7) expressed detectable levels of IL-8, even though two of them did not contain significant levels of IL-8 (Figure 4a and c). On the contrary, IL-8 was not detected in any of the ER-positive breast cancer tissues (Figure 4a and c). When we evaluated the expression at the mRNA level of IL-8 between two groups of seven ER-positive and ER-negative tumors, we found a significant difference between groups with a preferential expression of IL-8 only in the ER-negative tumors (P ¼ 0.001). We also assessed PR levels in the samples, but no correlation could be seen between PR and IL-8 levels ( Figure 4b ).
Our second objective was to evaluate whether IL-8 expression could be correlated to the higher invasiveness of ER-negative cancer cells. In vitro invasion test of the cells through a reconstituted basement membrane composed of matrigel was carried on in transwells. We observed that all ER-negative breast cancer cells except SKBR-3 (which do not express significant IL-8 levels) were highly invasive ( Figure 5a ). On the contrary, ERpositive breast cancer cells displayed a low, if any, 
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A Freund et al invasion ability (Figure 5b ). The same observation of a high invasion potential of ER-negative cancer cells was made for endometrium and ovary cancer cells, whereas ER-positive ovarian cancer cells displayed a low invasion ability, suggesting that it is a general phenomenon for cancer cells ( Figure 5c ). When comparing IL-8 levels to their invasion potential between the different cell lines, the Spearman and Kendall test showed that the two variables were correlated (K ¼ 0.5883 and Spa ¼ 0.7293).
The next step was to analyze the mechanisms by which IL-8 affects invasion and proliferation of cancer cells. IL-8 is acting through specific receptors (CXCR1 and CXCR2). Thus, to estimate IL-8's biological effects on cancer cells, it was important to check whether IL-8 receptors (CXCR1 and CXCR2) were present in the different cell lines. This was performed by RT-PCR to increase the sensitivity. CXCR1 receptors were expressed at very low levels (data not shown). On the contrary, CXCR2 was present in the different cell lines, with the exception of MCF-7 and MDA-MB-435 cells (Figure 6a) . No correlation could be seen between the ER status and the levels of CXCR2, as most of the ERnegative or -positive cell lines express rather high levels of this receptor.
To confirm IL-8 involvement in invasion, we performed in vitro invasion assays with ZR-75-1 cells, which had been transiently transfected with IL-8 sense (Figure 6b ). This enabled us to follow only transfected cells. ZR-75-1 cells that had been transfected by IL-8 sense vector displayed a two fold enhanced invasion, whereas the antisense version had no effect, presumably because of the very low levels of IL-8 in these cells (Figure 6b ). On the other hand, addition of recombinant IL-8 to the medium also led to an increase of invasion of ZR-75-1 cells. These data confirm that IL-8 is playing a role in the invasion of cancer cells. Interestingly, transfection of IL-8 antisense construct in ER-negative MDA-MB-231 cells decreased by about 20% the invasiveness of the cells, confirming the proinvasive role of IL-8 ( Figure 6c) .
As IL-8 was affecting invasion, we were wondering if it could also modify the in vitro proliferation of breast cancer cells. We thus treated ZR-75-1 and MDA-MB-231 cells with two doses of IL-8 (Figure 6d ). IL-8 did not affect the proliferation of both types of cells, although these cells express IL-8 receptors (Figure 6a ), confirming that IL-8's primary role was linked to invasion.
Discussion
Members of the a-chemokine family such as IL-8 have been considered as tumor cell products potentially involved in growth and progression of tumors. The goal of this study was to evaluate whether IL-8 was linked or not to ER status and whether IL-8 could account for the higher aggressiveness of ER-negative breast cancer cells.
Cloning of IL-8 cDNA from MDA-MB-231 cells reveals that its sequence is totally identical to the known 99 amino acid precursor protein at IL-8. A functional 79 amino acid protein is secreted from the cells after cleavage of a 90 amino acid signal peptide. The N-terminal extracellular processing of secreted IL-8 yields several biological active variants, with the 72 amino acid variant being the predominant form (Terui et al., 1999) .
More importantly, we show that IL-8 is overexpressed in ER-negative breast cancer cells. IL-8 expression is strongly different between ER-negative and ER-positive breast cancer cells. Not only IL-8 RNA, but also IL-8 secretion levels in the culture medium were extremely (Brew et al., 1997) , melanoma (Schadendorf et al., 1993) , prostate (Greene et al., 1997) , ovary (Lee et al., 2000; Xu and Fidler, 2000) or breast (Basolo et al., 1993; Green et al., 1997; Youngs et al., 1997; De Larco et al., 2001) ; but to our knowledge, this is the first demonstration of an inverse correlation between ERa status and IL-8 expression. IL-8 is found not only in normal but also in cancerous breast (Basolo et al., 1993) .
--------------------------------------------------------"
Some studies suggest that patients with recurrent prostate, breast or ovarian cancer exhibit higher levels of IL-8 in serum or peripherical blood leukocytes (Merogi et al., 1997; Ivarsson et al., 1998; Veltri et al., 1999) and in cancer tissues (Green et al., 1997) . On the contrary, other studies show that IL-8 expression in breast tumors is identical between normal and cancer tissues (Speirs et al., 1996) . Interestingly, IL-6 expression has been correlated with ER status (Fontanini et al., 1999) , which suggests that IL-6 and IL-8 are opposite markers.
Concerning IL-8 receptors, we observed that CXCR1 expression was extremely low in all lines tested, whereas most of the cells investigated showed a nice expression of CXCR2, without any correlation with ER status. CXCR1 and CXCR2 that are encoded by two distinct genes (Sprenger et al., 1994a, b) have been shown to be expressed in most cancer cells with no apparent correlation with the grade of the tumor (Miller et al., 1998; Muller et al., 2001) . On the contrary, Muller et al. (2001) have recently shown that CXCR4 and CCR7, two other chemokine receptors that are involved in chemotactic and invasive responses, were highly expressed in breast cancer cells as well as malignant breast tumors and metastases. Our results suggest that IL-8 content, but not CXCR1 or CXCR2 expression, can be considered as markers of ER-negative breast cancers.
An important question was to estimate whether IL-8 expression could be correlated to the invasive potential of the ER-negative breast cancer cell lines. We demonstrated that most of the ER-negative breast or ovarian cancer cells exhibited a higher invasion rate compared to ER-positive cancer cells whose migration was uniformly low, suggesting a general inverse correlation between the ER status and the invasion potential of the cells. This correlation was not true for all cells, suggesting that other factors might modulate the invasive potential of each cell. This is in agreement with several reports describing that ER-positive breast cancer cells are generally less invasive than ER-negative breast cancer cells (Madsen and Briand, 1990; Thompson et al., 1992; Sommers et al., 1994) . The lack of ER in human breast cancers is associated with a poorer prognosis (Skoog et al., 1987) . In addition, exogenous expression of ER downregulated IL-8 expression as shown in Hela cells. It is worthwhile to point out that we and others previously showed that introduction of ERa or ERb in ERnegative breast cancer cells leads to a decreased invasiveness of the cells (Garcia et al., 1992; Lazennec et al., 2001) . To date, no real explanation could be given to such a phenomenon. Our new data suggest that the decreased expression of IL-8 in cells transfected with ERa or ERb could account, at least in part, for the reduced invasiveness of these cells.
Moreover, we also show that exogenous expression of IL-8 increases by twofold the invasion rate of ERpositive breast cancer cells, without affecting the in vitro proliferation rate of these cells, confirming the proinvasive role of IL-8. When IL-8 is transfected in cancer cells, both tumor inhibition (Nakashima et al., 1996; Lee et al., 2000) and promotion (Luca et al., 1997; Inoue et al., 2000) have been observed in vivo, depending on the cell type.
Our data show that IL-8 expression is negatively correlated to ER status and is expressed preferentially in invasive cancer cells, which suggests a potential correlation between IL-8 expression and tumor progression/ invasiveness. However, available studies remain preliminary to conclude on this question. Indeed, in xenograft mouse models, this issue remains controversial. Most of the studies show that IL-8 expression is correlated with tumorigenesis of prostate (Greene et al., 1997) , ovary (Yoneda et al., 1998) and breast (De Larco et al., 2001) cancers. Other reports suggest that a high expression of IL-8 inhibits tumor progression of ovarian cancers (Lee et al., 2000) and has negligible effect on prostate cancer (Balbay et al., 1999) development in nude mice. One hypothesis for IL-8 reduction of ovarian tumor progression in nude mice could be an increased neutrophil infiltration of the cancer tissues, leading to the release of proteases or apoptotic agents able to kill cancer cells. This hypothesis could account for the discrepancies between these studies.
Whether IL-8 expression is correlated with worse prognosis in humans, needs to be evaluated in breast cancer in patients. But, to date, no extensive study of large human breast tumor collection has been done, and it appears that there is no clear correlation between the IL-8 expression and metastatic potential of tumor cells representing different clinical stages, or with tumor prognosis.
Investigation of IL-8 involvement in cell proliferation, angiogenesis, migration or infiltration of host cells appears complex and will require a combined consideration of data obtained from cell cultures, animal models and vast clinical studies.
Materials and methods

Cell Culture
Cells were maintained in media recommended by ATCC, supplemented with 10% fetal calf serum (FCS) and gentamycin. For transfection assays, cells were seeded on six-well plates. To wean the cells off steroids, they were cultured in phenol red-free DMEM/F12 supplemented with 10% (charcoal dextran-treated FCS) (CDFCS) for 4 days.
Plasmids
A CMV-LUC reporter (Promega, Madison, WI, USA) was used as an internal control for invasion assays and corresponds to the luciferase gene under the control of the cytomegalovirus (CMV) promoter. pShuttle-IL-8 sense and pShuttle-IL-8 AS (antisense) contain the sequences 1-877 of human IL-8 cDNA cloned into pShuttle vector (Clontech, Palo Alto, CA, USA). The luciferase reporter plasmid ERE2-TK-LUC used to monitor estrogen responsiveness of our cells contains two copies of the consensus estrogen-responsive element (ERE) cloned upstream of the minimal herpes simplex virus thymidine kinase promoter. A CMV-GAL reporter was used as an internal control and corresponds to the b-galactosidase gene under the control of the CMV promoter.
Transient transfection
Cells (3 Â 10) 5 were plated in six-well plates in phenol red-free DMEM-F12 supplemented with 10% CDFCS 24 h before transfection. Transfections were performed by lipofection (lipofectamine, Invitrogen, Groningen, The Netherlands) using 2 mg of pShuttle, pShuttle-IL-8 sense or pShuttle-IL-8 AS, along with 2 mg of the internal reference reporter plasmid (CMV-LUC) per well. Cells were harvested and assayed for luciferase activity with Renilla Luciferase assay system 36 h after lipofection (Promega, Madison, WI) on an LKB luminometer. For the determination of estrogen-responsiveness of the cells, 2 mg of ERE2-TK.-LUC and 0.8 mg of internal control CMV-GAL per well were cotransfected by lipofection. b-galactosidase and luciferase were determined as previously described (Lazennec et al., 1997) .
RNA extraction and reverse transcriptase PCR
Total RNA was isolated with TRIzol reagent (Invitrogen) as described by the manufacturer. Reverse transcription was performed using random primers and Superscript II enzyme (Invitrogen). The PCR was performed with Platinium Taq polymerase (Invitrogen) and 1 : 40 of reverse transcription reaction. Cycles of 30 s at 941C, 1 min at 601C, and 1 min 30 s at 721C were done 29 times (ERa, rS9, CXCR2) 
Northern blot analysis
Equal amounts of RNA (20 mg per lane) were loaded on a 1% agarose-formaldehyde gel. RNA was then transferred to nylon membranes. Membranes were then hybridized with the different probes at 651C in hybridization solution (1 mm EDTA, 7% SDS, 0.5 m Na 2 HPO 4 , pH 7.2). A probe for human 28S was used to confirm equal loading of RNA in all the wells.
Whole-cell extract preparation and Western blot
Cell extracts were prepared as described previously (Lazennec et al., 2001) . A total of 30 mg whole-cell extract proteins were subjected to SDS-PAGE followed by electrotransfer onto a nitrocellulose membrane. The blot was probed with anti-IL-8 antibody (MAB-208, R&D Systems, Minneapolis, MN, USA) (1 : 1000) and then incubated with goat anti-mouse Gig horseradish peroxidase conjugated antibody (1 mg/ml). An ECL kit (Amersham Pharmacia Biotech, Arlington, IL, USA) was used for detection.
IL-8 ELISA
The IL-8 concentration in culture supematants was determined by ELISA as recommended by the manufacturer. Briefly, samples were added to 96-well microtiter plates, which were coated with monoclonal anti-IL-8 antibody (MAB-208, 4 mg/ ml, R&D Systems, Minneapolis, MN, USA). After 2 h, the wells were washed three times and biotinylated anti-IL-8 antibody (BAF-208, 20 ng/ml, R&D Systems) was added. After 2 h of incubation, the plates were washed three times, and streptavidin-HRP conjugate (RPN1231, AmershamPharmacia, Buckinghamshire, UK) supplied, and the plates incubated for 20 min. Plates were washed again and chromogen substrate (Sigma Fast OPD, Sigma, St Louis, MO, USA) added. The plates were read at 450 nm.
Recombinant adenovirus construction, propagation and infection
The adenoviruses used in this study have been described previously (Lazennec et al., 2001) . Briefly, the complete coding sequence of wild-type human ER (hERa) or hERb cDNAs was subcloned in BamHI site of the pACsk12CMV5 shuttle vector. To obtain recombinant viruses, permissive HEK-293 cells (human embryonic kidney cells) were cotransfected with pACsk12CMV5 or the recombinant pACsk12CMV5-hER plasmid and with pJM17, which contains the remainder of the adenoviral genome. In vivo recombination of the plasmids generates infectious viral particles, nonrecombinant adenovirus Ad5 or recombinant adenovirus Ad-hERa and Ad-hERb. Hela cells were infected overnight at a multiplicity of infection (MOI) of 100 with the different adenoviruses in DMEM/F12 10% CDFCS. The next day, the medium was changed and the cells were let to express IL-8 for 48 h before collecting the medium.
Invasion through Matrigel, Renilla Luciferase Assay and MTT assay
Cells were grown overnight in six well culture plates in DMEM/F12 supplemented with 10% FCS. In all, 2 mg of pShuttle IL-8 sense or pShuttle IL-8 AS, or 2 mg of control vector pShuttle, was cotransfected with 2 mg of CMV-LUC vector as mentioned above. Invasion assay was as previously described using 12-well polycarbonate filter (12 mm pore size) Transwells (Corning-Costar, Coming, NY, USA) (Platet and Garcia, 1998) . After 24 h of migration, cells that had migrated to the lower side of the filter and cells present in the control plates were collected and luciferase activity was measured as described above. The percentage of Matrigel-invading cells was represented by the ratio of luciferase activity of invasive cells to luciferase activity of total cells.
The same type of experiments was also performed without transfection to determine the invasion potential of each cell line as described earlier (Lazennec et al., 2001) .
Cell proliferation studies
Cells were maintained for 4 days in 10% CDFCS DMEM/F12 and then seeded at 20 000 cells/well in 24-well dishes in 10% CDFCS DMEM/F12, complemented or not with recombinant human IL-8 (R&D Systems, Minneapolis, MN, USA). After 2, 4, or 6 days, the total cell DNA was quantified by diamino benzoic acid (DABA) as described earlier (Lazennec et al., 2001) .
Tumor material and tumor sample processing
The study included 14 primary breast invasive ductal carcinoma sent to the laboratory for routine analysis of ER and PR status. Frozen biopsy samples were ground to a fine powder in liquid nitrogen and subsequently homogenized in a 10 mm Tris pH 7.4, 1.5 mm EDTA, 4.2 mm thioglycerol, 5 mm molybdic acid, using a Dounce homogenizer. The homogenates were spun at 100 000 g for 1 h at 41C, yielding 100 000 g supernatants immediately used for ER and PR evaluation using the ABBOTT ER EIA Monoclonal Kit and the ABBOTT PR Monoclonal kit (ABBOTT, Rungis, France).
Statistical analysis
To compare IL-8 secretion levels or invasion potential between the different populations of cell lines, the Kruskal-Wallis oneway analysis of variance by ranks was used since the variable analyzed was not normally distributed, the groups being independent. To look for a correlation between IL-8 secretion levels and invasion potential of the cell lines, we have estimated the Kendall and Spearman rank correlation coefficients and have then tested them against the null value. The significance level of the P value was set at 0.05 for all tests.
